ANXA1 and neoplasm: The receptor-ligand mode of action between tumor cells and immune cells in LUAD patients (MDK-NCL, ANXA1-FPR1, LGALS9-CD45, LGALS9-CD44, and CXCL-CXCR et al.)may serve as targets for immunotherapy.